Contact us here

Work Package 5: Data analytics

The main aim of WP5 is to carry out analyses of the data sources identified and collated by WP3 and WP4 based on the core outcome sets for localised, locally advanced, and advanced-metastatic prostate cancer identified by WP2 in order to answer, or provide opportunities to answer, the main questions related to prostate cancer.


  1. Develop a data analysis plan and standard operating procedure for each major research objective to ensure transparency and effective communication for all stakeholders.
  2. Carry out data exploration, visualisation and basic statistics in a way that uncovers new insights into the research questions being asked.
  3. Implement data quality control measures to ensure data errors and outliners are identified and controlled for ensuring the most reliable data possible.
  4. Develop predictive models of patients outcomes, disease progression and therapy selection based on advanced analytics. This will include investigating the added value of clinical and biological biomarkers in improving predictions throughout the care pathway of prostate cancer.
  5. Assess the performance of new predictive models over existing methods and develop a clinician/patient scoring and evaluation process.
  6. Pilot patient evaluation and treatment strategies based on these new predictive analytical tools and models, as it is vitally important to measure the acceptance and adherence of both patients and clinicians.
  7. Utilise the PIONEER database to estimate the economic burden of prostate cancer depending on the disease stage and geographic region in which the patient lives. The outputs will be useful to inform policy issues, and provide useful inputs to WP6.

Dissemination of all new insights, individually tailored risk predictions and proposed algorithms will occur via recommendations and guidelines. The dissemination measures will be undertaken in close collaboration with WP7.

WP5 Partners

ASSOCIATION EISBM, Erasmus Universitair Medisch Centrum Rotterdam, Universitaetsklinikum Hamburg-Eppendorf, European Organisation for Research and Treatment of Cancer, Imperial College of Science Technology and Medicine, Weizmann Institute of Science, Fraunhofer IZI, Swedish Institute for Health Economics, Astellas Pharma, SAS Institute, Orion Corporation and Bayer.